Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer

Completed · Phase 3

Conditions studied: Lung Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if topotecan is more effective given by infusion or by mouth. PURPOSE: Randomized phase III trial to compare the effectiveness of topotecan given by infusion with that of topotecan given by mouth in treating patients who have small cell lung cancer that has relapsed following previous therapy.

Key facts

Study ID
NCT00003917
Run by
Case Comprehensive Cancer Center
People needed
4
Starts
1999-03-01
Expected to finish
2001-11-01
Last updated by the study team
2014-01-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.